Hefei Lifeon Pharmaceutical Co., Ltd. (SHE:003020)

SHE:003020 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,444	1,488	1,887	2,570	2,261	1,882
Other Revenue	30.32	30.32	14.25	8.86	11.77	12.73
Revenue	1,474	1,518	1,901	2,579	2,273	1,894
Revenue Growth (YoY)	-1.82%	-20.11%	-26.31%	13.46%	20.01%	14.80%
Cost of Revenue	524	479.46	932.11	1,619	1,369	1,262
Gross Profit	950.05	1,039	968.68	960.28	904.36	632.6
Selling, General & Admin	687.93	772.94	659.7	675.31	650.1	432.84
Research & Development	109.01	91.78	84.96	73.8	65.86	43.31
Other Operating Expenses	24.42	19.31	14.97	15.96	16.06	12.39
Operating Expenses	823.49	887.09	762.82	765.5	731.99	489.05
Operating Income	126.56	151.94	205.85	194.78	172.36	143.55
Interest Expense	-2.08	-1.92	-1.28	-0.89	-1.36	-0.24
Interest & Investment Income	31.85	13.62	32.14	36.68	14.58	4.3
Currency Exchange Gain (Loss)	0.01	0.01	0.04	0.4	-0.18	-0.49
Other Non Operating Income (Expenses)	-0.7	-0.75	0.92	-0.17	-0.34	-0.15
EBT Excluding Unusual Items	155.64	162.9	237.67	230.81	185.06	146.96
Gain (Loss) on Sale of Investments	0.44	1.6	0.32	-0.04	-0.01	-
Gain (Loss) on Sale of Assets	-0.13	0.02	-	-2.54	-0.03	-0.03
Asset Writedown	-6.97	-6.43	-0.12	-0.39	-0.27	-0.06
Other Unusual Items	28.38	13.72	19.55	11.98	10.09	10.07
Pretax Income	177.36	171.82	257.42	239.82	194.84	156.94
Income Tax Expense	17.42	19.34	23.53	30.57	22.61	21.82
Earnings From Continuing Operations	159.94	152.48	233.88	209.25	172.23	135.12
Minority Interest in Earnings	2.62	8.12	-7.21	-	-	-
Net Income	162.56	160.6	226.67	209.25	172.23	135.12
Net Income to Common	162.56	160.6	226.67	209.25	172.23	135.12
Net Income Growth	-6.72%	-29.15%	8.33%	21.50%	27.47%	28.51%
Shares Outstanding (Basic)	191	191	192	189	188	141
Shares Outstanding (Diluted)	191	191	192	189	188	141
Shares Change (YoY)	-0.64%	-0.47%	1.75%	0.49%	33.01%	0.03%
EPS (Basic)	0.85	0.84	1.18	1.11	0.92	0.96
EPS (Diluted)	0.85	0.84	1.18	1.11	0.92	0.96
EPS Growth	-6.13%	-28.81%	6.47%	20.90%	-4.17%	28.47%
Free Cash Flow	121.41	43.05	6.14	-45.79	-28.24	116.29
Free Cash Flow Per Share	0.64	0.23	0.03	-0.24	-0.15	0.82
Dividend Per Share	0.500	0.500	0.417	0.321	0.345	0.246
Dividend Growth	-18.92%	19.99%	30.02%	-7.16%	40.04%	-
Gross Margin	64.45%	68.42%	50.96%	37.23%	39.78%	33.40%
Operating Margin	8.59%	10.01%	10.83%	7.55%	7.58%	7.58%
Profit Margin	11.03%	10.58%	11.92%	8.11%	7.58%	7.13%
Free Cash Flow Margin	8.24%	2.83%	0.32%	-1.77%	-1.24%	6.14%
EBITDA	230.87	226.84	241.56	220.72	199.92	159.5
EBITDA Margin	15.66%	14.94%	12.71%	8.56%	8.79%	8.42%
D&A For EBITDA	104.3	74.91	35.71	25.94	27.55	15.95
EBIT	126.56	151.94	205.85	194.78	172.36	143.55
EBIT Margin	8.59%	10.01%	10.83%	7.55%	7.58%	7.58%
Effective Tax Rate	9.82%	11.25%	9.14%	12.75%	11.60%	13.91%
Revenue as Reported	1,474	1,518	1,901	2,579	2,273	1,894

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.